Adial Pharmaceuticals, Inc.: 10-Q filed 2019-11-14
What Adial Pharmaceuticals, Inc. reported in its quarterly report filed 2019-11-14 (fiscal Q3 2019): 25 published measures, 77 facts as tagged in accession 0001213900-19-023298.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-11-14
- Fiscal period
- fiscal Q3 2019
- Accession
- 0001213900-19-023298 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Adial Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 9,506,926 | USD | |
| At 2018-12-31 | 4,699,285 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 8,729,980 | USD | |
| At 2019-06-30 | 10,060,816 | USD | |
| At 2019-03-31 | 11,730,737 | USD | |
| At 2018-12-31 | 4,441,311 | USD | |
| At 2018-09-30 | 4,929,368 | USD | |
| At 2018-06-30 | -1,293,517 | USD | |
| At 2018-03-31 | -1,307,342 | USD | |
| At 2017-12-31 | -997,553 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 8,529,681 | USD | |
| At 2018-12-31 | 3,869,043 | USD | |
| At 2018-09-30 | 4,816,705 | USD | |
| At 2017-12-31 | 18,248 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -1,715,883 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -6,532,941 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -8,190,924 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -10,362,230 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | -4,585,876 | USD | 273 |
| 2018-01-01 to 2018-09-30 | -1,394,475 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 9,246,514 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 6,192,932 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | -18,568,311 | USD | |
| At 2018-12-31 | -12,035,370 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 384,869 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 1,133,333 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 3,468,172 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 5,068,514 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -1,745,742 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -6,154,018 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -3,816,099 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -5,897,079 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 9,500,615 | USD | |
| At 2018-12-31 | 4,692,550 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 776,946 | USD | |
| At 2018-12-31 | 257,974 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 475,086 | USD | |
| At 2018-12-31 | 82,680 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 6,311 | USD | |
| At 2018-12-31 | 6,735 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 1,745,742 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 6,154,018 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 3,816,099 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 5,897,079 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 864,280 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 2,761,630 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 188,435 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 320,838 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 10,294,860 | shares | |
| At 2018-12-31 | 6,862,499 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 27,287,996 | USD | |
| At 2018-12-31 | 16,469,818 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 6,311 | USD | |
| At 2018-12-31 | 6,735 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-09-30 | 510,879 | USD | |
| At 2018-12-31 | 317,547 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -1,715,883 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -6,532,941 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -8,190,924 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -10,362,230 | USD | 273 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | -1,715,883 | USD | 92 |
| 2019-04-01 to 2019-06-30 | -2,134,407 | USD | 91 |
| 2019-01-01 to 2019-03-31 | -2,682,651 | USD | 90 |
| 2018-07-01 to 2018-09-30 | -8,190,924 | USD | 92 |
| 2018-04-01 to 2018-06-30 | -1,792,356 | USD | 91 |
| 2018-01-01 to 2018-03-31 | -378,950 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 881,462 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 3,392,388 | USD | 273 |
| 2018-07-01 to 2018-09-30 | 3,627,664 | USD | 92 |
| 2018-01-01 to 2018-09-30 | 5,576,241 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-09-30 | 424 | USD | 273 |
| 2018-01-01 to 2018-09-30 | 423 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-07-01 to 2019-09-30 | 29,859 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -378,923 | USD | 273 |
| 2018-07-01 to 2018-09-30 | -4,374,825 | USD | 92 |
| 2018-01-01 to 2018-09-30 | -4,465,151 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-09-30 | 38,160 | USD | 273 |
Inspect the source
- Entity
- Adial Pharmaceuticals, Inc. / CIK 0001513525
- Captured
- 2026-09-20T09:13:16.139Z
- SEC response SHA-256
a18f3033034427d32ef6db390e21f05d7acd23d932b720bc7458a3fbeee3e90d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001513525.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))